The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The trial also demonstrated significant improvements across multiple secondary endpoints
Capital infusion to accelerate Earendil’s R&D platform
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Subscribe To Our Newsletter & Stay Updated
